{"schema_version":"secwatch.filing_event.v1","accession":"0001588978-21-000007","form_type":"8-K","ticker":"PRCT","cik":"0001588978","company_name":"PROCEPT BioRobotics Corp","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.171512+00:00","generated_at":"2026-06-28T18:01:02.721041+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"PROCEPT BioRobotics appoints Elisabeth Sandoval to Board of Directors","bullets":["Board expanded from eight to nine members; Sandoval appointed as Class I director effective Oct. 21, 2021.","Sandoval is a healthcare executive with prior roles at Allergan (20+ years) and as CCO of Kythera Biopharmaceuticals and Alder Biopharmaceuticals.","She will receive a restricted stock unit award valued at $200,000, vesting over three years.","Sandoval also serves on boards of Intersect ENT, Satsuma Pharmaceuticals, Vyne Therapeutics, and Alastin Skincare.","CEO Reza Zadno cited her commercial expertise to accelerate Aquablation therapy adoption for BPH."],"urls":{"canonical":"https://secwatch.observer/filing/0001588978-21-000007","json":"https://secwatch.observer/filing/0001588978-21-000007.json","markdown":"https://secwatch.observer/filing/0001588978-21-000007.md","text":"https://secwatch.observer/filing/0001588978-21-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1588978/000158897821000007/0001588978-21-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1588978/000158897821000007/a8-kxelizabethsandoval.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:01:02.721041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7896a6b72e","claim":"Elisabeth Sandoval was appointed as Director at PROCEPT BioRobotics Corp.","evidence_excerpt":"Effective October 21, 2021, the Board of Directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) increased the number of directors on the Board from eight to nine and appointed Elisabeth Sandoval as a Class I director of the Company, with such appointment taking effect immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1588978/000158897821000007/0001588978-21-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}